The ADDF accelerates the discovery of drugs to prevent and treat Alzheimer's disease through research funding and portfolio management.
The Alzheimer's Drug Discovery Foundation (ADDF) is dedicated to advancing the discovery of drugs to prevent and treat Alzheimer's disease. ADDF funds research programs focused on drug development, biomarkers, and prevention strategies. In 2024, ADDF catalyzed significant breakthroughs, including major investments in scalable blood tests and the cataloging of Alzheimer's biomarkers. The foundation also marked the 10th anniversary of the Goodes Prize and celebrated the FDA approval of Kisunla (Donanemab). ADDF's diverse portfolio is one of the largest worldwide, emphasizing lifestyle interventions and innovative diagnostics.
The Chinese Psychological Society is a professional academic organization in the field of psychology in China, dedicated to advancing psychological research, education, and applications.
The Department of Psychological & Brain Sciences at Boston University is a globally recognized leader in research. It offers expertise in a broad range of fields and is ranked highly for its combined psychiatry/psychology faculty research strength.
The Accelerating Medicines Partnership (AMP) Schizophrenia (SCZ) program addresses the need for more effective treatments for schizophrenia and related mental health conditions.